Robert C Bast

List of Publications by Citations

434 papers	45,363 citations	95 h-index	203 g-index
521 ext. papers	49,966 ext. citations	6.4 avg, IF	6.77 L-index

#	Paper	IF	Citations
434	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
433	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
432	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *Journal of Clinical Oncology*, **2007**, 25, 5287-312	2.2	1760
431	A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *New England Journal of Medicine*, **1983**, 309, 883-7	59.2	1714
430	Reactivity of a monoclonal antibody with human ovarian carcinoma. *Journal of Clinical Investigation*, **1981**, 68, 1331-7	15.9	1168
429	ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *Journal of Clinical Oncology*, **2006**, 24, 5313-27	2.2	1129
428	The biology of ovarian cancer: new opportunities for translation. *Nature Reviews Cancer*, **2009**, 9, 415-28	31.3	1024
427	Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer*, **2011**, 11, 719-25	31.3	893
426	Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. *Cancer Research*, **2004**, 64, 5882-90	10.1	796
425	2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2001**, 19, 1865-78	2.2	643
424	Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. *New England Journal of Medicine*, **1988**, 318, 869-76	59.2	616
423	Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 11960-5	11.5	615
422	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nature Reviews Cancer*, **2015**, 15, 668-79	31.3	581
421	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecologic Oncology*, **2009**, 112, 40-6	4.9	557
420	The CA 125 tumour-associated antigen: a review of the literature. *Human Reproduction*, **1989**, 4, 1-12	5.7	551
419	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2016**, 34, 1134-50	2.2	543
418	Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. *Nature*, **1994**, 370, 558-61	50.4	541

417	The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. *Gynecologic Oncology*, **2008**, 108, 402-8	4.9	506
416	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. *Clinical Chemistry*, **2008**, 54, e11-79	5.5	451
415	Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **1996**, 14, 2843-77	2.2	440
414	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy*, **2021**, 17, 1-382	10.2	440
413	High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. *Journal of Clinical Oncology*, **1993**, 11, 1132-43	2.2	428
412	New tumor markers: CA125 and beyond. *International Journal of Gynecological Cancer*, **2005**, 15 Suppl 3, 274-81	3.5	366
411	Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. *Clinical Cancer Research*, **2004**, 10, 3291-300	12.9	358
410	Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. *American Journal of Clinical Pathology*, **1983**, 79, 98-104	1.9	307
409	High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. *Journal of Clinical Oncology*, **1988**, 6, 1368-76	2.2	306
408	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. *Journal of Clinical Investigation*, **2008**, 118, 3917-29	15.9	298
407	BCG and cancer (first of two parts). *New England Journal of Medicine*, **1974**, 290, 1413-20	59.2	287
406	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. *Molecular Cancer Therapeutics*, **2010**, 9, 3186-99	6.1	284
405	Potential markers that complement expression of CA125 in epithelial ovarian cancer. *Gynecologic Oncology*, **2005**, 99, 267-77	4.9	279
404	Elevated serum concentrations of CA-125 in patients with advanced endometriosis. *Fertility and Sterility*, **1986**, 45, 630-4	4.8	278
403	NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 214-9	11.5	262
402	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16472-7	11.5	256
401	Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. *Clinical Cancer Research*, **2005**, 11, 6116-26	12.9	250
400	Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. *American Journal of Obstetrics and Gynecology*, **1984**, 148, 1057-8	6.4	243

399	A genetically defined model for human ovarian cancer. *Cancer Research*, **2004**, 64, 1655-63	10.1	233
398	Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. *American Journal of Obstetrics and Gynecology*, **1991**, 164, 15-21	6.4	229
397	Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. *Oncogene*, **1999**, 18, 6635-40	9.2	226
396	Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. *Cancer Prevention Research*, **2011**, 4, 365-74	3.2	221
395	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. *Cancer*, **2012**, 118, 2603-14	6.4	220
394	Development of a multimarker assay for early detection of ovarian cancer. *Journal of Clinical Oncology*, **2010**, 28, 2159-66	2.2	219
393	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. *Molecular Carcinogenesis*, **2008**, 47, 701-6	5	218
392	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*, **2015**, 33, 2695-704	2.2	214
391	Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. *Endocrinology*, **2012**, 153, 1593-602	4.8	213
390	Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. *Journal of Clinical Oncology*, **2005**, 23, 7919-26	2.2	190
389	Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. *Cancer*, **1995**, 76, 2004-10	6.4	183
388	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. *American Journal of Obstetrics and Gynecology*, **1991**, 164, 669-74	6.4	182
387	Early detection of ovarian cancer. *Disease Markers*, **2007**, 23, 397-410	3.2	179
386	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology*, **2017**, 35, 2838-2847	2.2	178
385	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. *American Journal of Obstetrics and Gynecology*, **2010**, 203, 228.e1-6	6.4	173
384	Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. *American Journal of Obstetrics and Gynecology*, **1988**, 159, 341-6	6.4	172
383	Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. *American Journal of Obstetrics and Gynecology*, **1985**, 151, 981-6	6.4	159
382	Communication skills training in oncology **1999**, 86, 887-897		157

381	Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. *Gynecologic Oncology*, **2008**, 110, 196-201	4.9	154
380	Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. *Journal of Biological Chemistry*, **2004**, 279, 9653-61	5.4	153
379	Status of tumor markers in ovarian cancer screening. *Journal of Clinical Oncology*, **2003**, 21, 200s-205s	2.2	153
378	BCG and cancer. *New England Journal of Medicine*, **1974**, 290, 1458-69	59.2	152
377	Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. *Gynecologic Oncology*, **2003**, 88, 73-9	4.9	150
376	AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. *Clinical Cancer Research*, **2010**, 16, 3299-318	12.9	149
375	Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. *American Journal of Obstetrics and Gynecology*, **1984**, 149, 553-9	6.4	148
374	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. *International Journal of Gynecological Cancer*, **2016**, 26, 43-51	3.5	143
373	Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. *Journal of Clinical Oncology*, **2004**, 22, 4059-66	2.2	140
372	High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. *American Journal of Medicine*, **1980**, 68, 370-6	2.4	140
371	HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. *Oncogene*, **2006**, 25, 6986-96	9.2	136
370	Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. *Cancer*, **1994**, 73, 2380-5	6.4	136
369	Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. *Oncogene*, **1997**, 15, 2589-96	9.2	134
368	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. *American Journal of Obstetrics and Gynecology*, **1994**, 170, 246-52	6.4	132
367	A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. *Cancer Prevention Research*, **2011**, 4, 375-83	3.2	130
366	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. *Cancer*, **2008**, 112, 1489-502	6.4	130
365	Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 15346-51	11.5	130
364	Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. *Clinical Cancer Research*, **2005**, 11, 2149-55	12.9	129

363	Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. *Human Pathology*, **1996**, 27, 1185-91	3.7	129
362	Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. *Cancer*, **2011**, 117, 1661-9	6.4	128
361	The p53 tumor suppressor gene frequently is altered in gynecologic cancers. *American Journal of Obstetrics and Gynecology*, **1994**, 170, 246-252	6.4	120
360	Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. *Gynecologic Oncology*, **2010**, 117, 440-5	4.9	119
359	The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. *Journal of Biological Chemistry*, **2003**, 278, 23441-50	5.4	117
358	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. *Journal of Clinical Oncology*, **2019**, 37, 1956-1964	2.2	113
357	The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. *Cancer*, **2006**, 107, 2730-40	6.4	113
356	HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. *Cell Cycle*, **2005**, 4, 87-95	4.7	113
355	Correlation between CpG methylation profiles and hormone receptor status in breast cancers. *Breast Cancer Research*, **2007**, 9, R57	8.3	112
354	1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **1998**, 16, 793-5	2.2	109
353	Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. *Journal of Clinical Investigation*, **1989**, 83, 921-6	15.9	109
352	Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. *International Journal of Cancer*, **1994**, 56, 552-9	7.5	108
351	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. *Clinical Cancer Research*, **2004**, 10, 3919-26	12.9	106
350	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. *Mayo Clinic Proceedings*, **2015**, 90, 996-1000	6.4	105
349	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. *Cancer*, **2011**, 117, 4424-38	6.4	105
348	Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. *Journal of Medicinal Chemistry*, **2011**, 54, 3549-63	8.3	104
347	CA 125 serum levels correlated with second-look operations among ovarian cancer patients. *Obstetrics and Gynecology*, **1986**, 67, 685-9	4.9	104
346	Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. *American Journal of Obstetrics and Gynecology*, **2012**, 206, 349.e1-7	6.4	102

345	Early detection of ovarian cancer: promise and reality. *Cancer Treatment and Research*, **2002**, 107, 61-97	3.5	102
344	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. *Molecular Cell*, **2016**, 61, 520-534	17.6	101
343	SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. *Cancer Cell*, **2010**, 18, 109-21	24.3	101
342	The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. *American Journal of Obstetrics and Gynecology*, **1986**, 155, 56-60	6.4	101
341	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. *American Journal of Obstetrics and Gynecology*, **1991**, 164, 745-50	6.4	100
340	High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. *Journal of Clinical Oncology*, **1986**, 4, 646-54	2.2	95
339	Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *American Journal of Obstetrics and Gynecology*, **2012**, 206, 351.e1-8	6.4	93
338	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. *Cancer Cell*, **2016**, 30, 273-289	24.3	92
337	A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. *Human Molecular Genetics*, **1994**, 3, 589-94	5.6	92
336	p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. *Journal of Histochemistry and Cytochemistry*, **1992**, 40, 1047-51	3.4	92
335	Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. *Gynecologic Oncology*, **1995**, 59, 111-6	4.9	91
334	Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. *American Journal of Obstetrics and Gynecology*, **1992**, 166, 997-1007	6.4	91
333	A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. *Cancer*, **2013**, 119, 3454-61	6.4	90
332	Stanniocalcin 1 and ovarian tumorigenesis. *Journal of the National Cancer Institute*, **2010**, 102, 812-27	9.7	90
331	Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. *Journal of Biological Chemistry*, **2004**, 279, 4339-45	5.4	90
330	An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. *Gynecologic Oncology*, **1988**, 30, 7-14	4.9	90
329	ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. *Oncogene*, **2003**, 22, 2897-909	9.2	89
328	Cell Origins of High-Grade Serous Ovarian Cancer. *Cancers*, **2018**, 10,	6.6	87

327	Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. *Annals of the New York Academy of Sciences*, **1976**, 277, 60-93	6.5	86
326	Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. *American Journal of Obstetrics and Gynecology*, **1992**, 166, 676-84	6.4	85
325	Somatic activation of rasK gene in a human ovarian carcinoma. *Science*, **1984**, 223, 698-701	33.3	83
324	Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. *Clinical Cancer Research*, **2014**, 20, 5708-19	12.9	82
323	The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. *Cancer Microenvironment*, **2010**, 3, 137-47	6.1	81
322	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. *Cancer*, **2001**, 92, 2837-44	6.4	81
321	Linking genomic reorganization to tumor initiation via the giant cell cycle. *Oncogenesis*, **2016**, 5, e281	6.6	81
320	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. *Gynecologic Oncology*, **2007**, 107, 526-31	4.9	80
319	Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. *Gynecologic Oncology*, **1990**, 36, 299-305	4.9	80
318	Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. *Gynecologic Oncology*, **1985**, 22, 115-20	4.9	78
317	Prevention and early detection of ovarian cancer: mission impossible?. *Recent Results in Cancer Research*, **2007**, 174, 91-100	1.5	78
316	CA 125 in Ovarian Cancer: Advances and Controversy. *Clinical Chemistry*, **1998**, 44, 1379-1380	5.5	77
315	Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. *Gynecologic Oncology*, **2001**, 80, 245-53	4.9	76
314	Clinically relevant microRNAs in ovarian cancer. *Molecular Cancer Research*, **2015**, 13, 393-401	6.6	75
313	The role of biomarkers in the management of epithelial ovarian cancer. *Expert Review of Molecular Diagnostics*, **2017**, 17, 577-591	3.8	74
312	Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. *Gynecologic Oncology*, **1996**, 62, 89-99	4.9	74
311	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. *Cancer*, **1995**, 76, 2092-6	6.4	74
310	Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. *International Journal of Cancer*, **1983**, 32, 547-54	7.5	74

309	Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. *Cancer Research*, **2006**, 66, 2740-8	10.1	72
308	Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. *American Journal of Obstetrics and Gynecology*, **1994**, 170, 1177-83	6.4	72
307	Epidermal growth factor receptor expression in normal and malignant endometrium. *American Journal of Obstetrics and Gynecology*, **1989**, 161, 1247-52	6.4	72
306	4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. *Journal of Clinical Oncology*, **1991**, 9, 85-93	2.2	72
305	Current state of biomarker development for clinical application in epithelial ovarian cancer. *Gynecologic Oncology*, **2010**, 116, 240-5	4.9	71
304	Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. *Cancer*, **1993**, 71, 3942-6	6.4	71
303	The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. *Oncogene*, **2012**, 31, 68-79	9.2	70
302	Epigenetic regulation of ARHI in breast and ovarian cancer cells. *Annals of the New York Academy of Sciences*, **2003**, 983, 268-77	6.5	69
301	Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. *Cancer*, **2012**, 118, 91-100	6.4	68
300	Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. *Gynecologic Oncology*, **1994**, 52, 232-6	4.9	68
299	Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. *Oncogene*, **2016**, 35, 2506-17	9.2	67
298	Expression of p16 induces transcriptional downregulation of the RB gene. *Oncogene*, **1998**, 16, 1-8	9.2	67
297	Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. *Journal of Biological Chemistry*, **2004**, 279, 7576-83	5.4	67
296	Src family kinases and paclitaxel sensitivity. *Cancer Biology and Therapy*, **2011**, 12, 260-9	4.6	66
295	Cell growth regulation in epithelial ovarian cancer. *Cancer*, **1993**, 71, 1597-601	6.4	66
294	Dasatinib induces autophagic cell death in human ovarian cancer. *Cancer*, **2010**, 116, 4980-90	6.4	65
293	Translational crossroads for biomarkers. *Clinical Cancer Research*, **2005**, 11, 6103-8	12.9	64
292	Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. *Gynecologic Oncology*, **1999**, 73, 56-61	4.9	64

291	Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. *Autophagy*, **2017**, 13, 506-521	10.2	63
290	Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. *Journal of Biological Chemistry*, **1997**, 272, 13683-9	5.4	63
289	Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. *Cancer Research*, **2003**, 63, 4174-80	10.1	63
288	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. *Gynecologic Oncology*, **2012**, 126, 47-53	4.9	62
287	Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. *Human Molecular Genetics*, **2003**, 12, 1791-800	5.6	62
286	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. *American Journal of Obstetrics and Gynecology*, **1991**, 165, 1356-62	6.4	62
285	Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. *Gynecologic Oncology*, **2011**, 122, 548-53	4.9	61
284	Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. *Journal of the National Cancer Institute*, **2001**, 93, 1437-9	9.7	60
283	Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. *Experimental Cell Research*, **1993**, 207, 332-9	4.2	60
282	Overexpression of kallikrein 10 in epithelial ovarian carcinomas. *Gynecologic Oncology*, **2003**, 90, 44-50	4.9	59
281	Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. *Cancer*, **1994**, 74, 93-9	6.4	58
280	Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. *American Journal of Obstetrics and Gynecology*, **1991**, 165, 640-6	6.4	58
279	Early detection of ovarian cancer. *Biomarkers in Medicine*, **2008**, 2, 291-303	2.3	57
278	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. *Carcinogenesis*, **2007**, 28, 174-82	4.6	57
277	Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. *BMC Cancer*, **2011**, 11, 22	4.8	56
276	Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. *Cellular Immunology*, **1974**, 10, 248-59	4.4	56
275	Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. *American Journal of Clinical Pathology*, **1994**, 101, 192-7	1.9	55
274	Autologous bone marrow transplantation for acute lymphoblastic leukemia. *Journal of Clinical Oncology*, **1989**, 7, 1594-601	2.2	55

273	Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. *Clinical Immunology and Immunopathology*, **1983**, 28, 101-14		55
272	Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. *PLoS ONE*, **2012**, 7, e41170	3.7	54
271	Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. *Clinical Cancer Research*, **2004**, 10, 6559-66	12.9	54
270	Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. *Journal of Clinical Oncology*, **2001**, 19, 1716-22	2.2	54
269	Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. *Cancer Research*, **2002**, 62, 7264-72	10.1	54
268	Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. *Clinical Cancer Research*, **2005**, 11, 632-7	12.9	54
267	ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. *Cell Death and Differentiation*, **2014**, 21, 1275-89	12.7	53
266	Early Detection of Ovarian Cancer. *Hematology/Oncology Clinics of North America*, **2018**, 32, 903-914	3.1	53
265	Personalizing therapy for ovarian cancer: BRCAness and beyond. *Journal of Clinical Oncology*, **2010**, 28, 3545-8	2.2	52
264	Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. *Gynecologic Oncology*, **2007**, 106, 490-7	4.9	52
263	Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. *American Journal of Obstetrics and Gynecology*, **1993**, 169, 690-4	6.4	52
262	Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. *International Journal of Cancer*, **1993**, 53, 401-8	7.5	52
261	Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. *Cell Cycle*, **2008**, 7, 3747-58	4.7	51
260	Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. *Clinical Cancer Research*, **2004**, 10, 3881-4	12.9	51
259	Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. *International Journal of Gynecological Cancer*, **2012**, 22 Suppl 1, S5-8	3.5	50
258	Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. *Oncogene*, **2003**, 22, 484-97	9.2	50
257	Low-grade serous carcinoma: new concepts and emerging therapies. *Gynecologic Oncology*, **2013**, 130, 660-6	4.9	49
256	Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. *Journal of Biological Chemistry*, **2005**, 280, 2092-104	5.4	49

255	Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. *Methods in Enzymology*, **2006**, 407, 455-68	1.7	48
254	The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. *Cancer*, **1990**, 66, 431-6	6.4	48
253	Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. *Gynecologic Oncology*, **1999**, 75, 261-6	4.9	47
252	Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. *Clinical Cancer Research*, **2003**, 9, 3660-6	12.9	47
251	DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. *Autophagy*, **2014**, 10, 1071-92	10.2	46
250	CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. *Cancer*, **2010**, 116, 2850-3	6.4	46
249	Co-expression of human cancer-associated epitopes on mucin molecules. *International Journal of Cancer*, **1987**, 39, 68-72	7.5	46
248	Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. *Epigenetics*, **2013**, 8, 1330-46	5.7	45
247	Growth regulation and transformation of ovarian epithelium. *Cancer*, **1993**, 71, 545-51	6.4	45
246	Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. *Clinical Cancer Research*, **2006**, 12, 2404-13	12.9	45
245	Progress in the management of gynecologic cancer: consensus summary statement. *Journal of Clinical Oncology*, **2003**, 21, 129s-132s	2.2	45
244	Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. *Breast Cancer Research and Treatment*, **1996**, 41, 1-13	4.4	45
243	A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. *Cancer Prevention Research*, **2015**, 8, 37-48	3.2	44
242	Individualized care for patients with cancer - a work in progress. *New England Journal of Medicine*, **2004**, 351, 2865-7	59.2	44
241	ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. *International Journal of Cancer*, **2000**, 86, 690-4	7.5	44
240	Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. *BMC Cancer*, **2012**, 12, 243	4.8	43
239	Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. *Cancer Research*, **2011**, 71, 5806-17	10.1	43
238	Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. *BMC Cancer*, **2010**, 10, 378	4.8	43

237	High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. *Gynecologic Oncology*, **1990**, 38, 386-91	4.9	43
236	Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. *Nature*, **1974**, 250, 664-5	50.4	43
235	MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. *Differentiation*, **2008**, 76, 1081-92	3.5	42
234	Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. *American Journal of Obstetrics and Gynecology*, **1990**, 163, 1204-9	6.4	42
233	The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. *Oncology*, **2013**, 27, 548-56	1.8	42
232	Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. *Oncogene*, **2001**, 20, 8258-69	9.2	41
231	The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. *American Journal of Obstetrics and Gynecology*, **1990**, 163, 1164-7	6.4	41
230	Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. *Journal of Clinical Oncology*, **1985**, 3, 1355-63	2.2	41
229	More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. *Gynecologic Oncology*, **2011**, 121, 429-30	4.9	39
228	Targeted therapy for epithelial ovarian cancer: current status and future prospects. *International Journal of Gynecological Cancer*, **2003**, 13, 701-34	3.5	39
227	A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. *Cancer Research*, **2005**, 65, 6701-10	10.1	39
226	Fluorescence spectroscopy for in vivo characterization of ovarian tissue. *Lasers in Surgery and Medicine*, **2001**, 29, 128-35	3.6	39
225	Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. *Molecular Cancer Therapeutics*, **2007**, 6, 2843-57	6.1	38
224	ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. *Cell Death and Disease*, **2015**, 6, e1836	9.8	37
223	FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. *Cancer Research*, **2011**, 71, 6878-87	10.1	37
222	CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. *Acta Oncologica*, **1989**, 28, 655-7	3.2	37
221	A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. *Gynecologic Oncology*, **1998**, 70, 404-9	4.9	36
220	Pathogenesis of ovarian cancers. *Journal of the Society for Gynecologic Investigation*, **1994**, 1, 181-90		36

219	Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. *BJOG: an International Journal of Obstetrics and Gynaecology*, **1993**, 100, 1120-4	3.7	36
218	Lysophosphatidic acid prevents apoptosis in fibroblasts via Gi-protein-mediated activation of mitogen-activated protein kinase. *Biochemical Journal*, **2000**, 352, 135	3.8	35
217	Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. *Transplantation*, **1988**, 46, 57-60	1.8	35
216	Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. *Seminars in Oncology*, **2003**, 30, 93-104	5.5	34
215	Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. *American Journal of Obstetrics and Gynecology*, **1985**, 152, 1003-10	6.4	34
214	Tumor necrosis factor-□and interferon-□stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFB. *Oncotarget*, **2016**, 7, 14871-84	3.3	34
213	Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. *International Journal of Oncology*, **2013**, 43, 1194-204	4.4	33
212	Pros and cons of gynecologic tumor markers. *Cancer*, **1987**, 60, 1984-92	6.4	32
211	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. *Nature Communications*, **2018**, 9, 476	17.4	31
210	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1333-40	4	31
209	Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition. *EBioMedicine*, **2016**, 6, 149-161	8.8	31
208	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. *Clinical Cancer Research*, **2017**, 23, 5912-5922	12.9	31
207	Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. *Cancer Prevention Research*, **2012**, 5, 706-16	3.2	31
206	Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2001**, 1519, 216-22		31
205	Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. *Nuclear Medicine and Biology*, **1999**, 26, 781-90	2.1	31
204	Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. *American Journal of Clinical Pathology*, **1990**, 94, 8-13	1.9	31
203	CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. *International Journal of Gynecological Cancer*, **2013**, 23, 815-22	3.5	30
202	Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. *Oncogene*, **2012**, 31, 2450-60	5.2	30

201	Combined use of biomarkers for detection of ovarian cancer in high-risk women. *Tumor Biology*, **2010**, 31, 209-15	2.9	30
200	CA125/MUC16 is dispensable for mouse development and reproduction. *PLoS ONE*, **2009**, 4, e4675	3.7	30
199	RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. *Autophagy*, **2018**, 14, 637-653	10.2	29
198	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. *EBioMedicine*, **2016**, 10, 137-49	8.8	29
197	Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. *Cancer Letters*, **2012**, 326, 176-82	9.9	29
196	A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 2375-82	6.1	29
195	A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. *Journal of Experimental Therapeutics and Oncology*, **2012**, 10, 155-62	0.8	29
194	Potentially inappropriate medication use in older patients with breast and colorectal cancer. *Cancer* , **2018**, 124, 3000-3007	6.4	28
193	Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. *Clinical Chemistry*, **2013**, 59, 22-31	5.5	28
192	Urinary levels of Bcl-2 are elevated in ovarian cancer patients. *Gynecologic Oncology*, **2009**, 112, 60-7	4.9	28
191	Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. *Cancer Investigation*, **2004**, 22, 248-56	2.1	28
190	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. *Oncogene*, **2005**, 24, 6174-84	9.2	28
189	The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. *American Journal of Obstetrics and Gynecology*, **1993**, 168, 228-32	6.4	28
188	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. *American Journal of Obstetrics and Gynecology*, **1994**, 170, 1285-1296	6.4	28
187	Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. *Journal of Experimental Medicine*, **1971**, 133, 202-15	16.6	28
186	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. *Genes and Cancer*, **2016**, 7, 60-72	2.9	28
185	Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. *Laboratory Investigation*, **2016**, 96, 37-48	5.9	27
184	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. *Clinical Cancer Research*, **2017**, 23, 1945-1954	12.9	27

183	MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. *Cancer*, **2009**, 115, 3897-908	6.4	27
182	Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. *Cancer Discovery*, **2012**, 2, 16-8	24.4	27
181	Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. *Gynecologic Oncology*, **2001**, 80, 145-55	4.9	27
180	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. *American Journal of Obstetrics and Gynecology*, **1994**, 170, 1285-96	6.4	27
179	CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. *Gynecologic Oncology*, **1990**, 36, 161-5	4.9	27
178	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. *Cancer*, **2020**, 126, 894-907	6.4	27
177	FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. *Endocrine-Related Cancer*, **2013**, 20, 415-29	5.7	26
176	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. *Journal of the National Cancer Institute*, **2011**, 103, 1403-22	9.7	26
175	Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. *Journal of the National Cancer Institute*, **1976**, 56, 829-32	9.7	26
174	Heterogeneity of the cellular immune response. I. Kinetics of lymphocyte stimulation during sensitization and recovery from tolerance. *Journal of Experimental Medicine*, **1971**, 133, 187-201	16.6	26
173	Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. *Transactions of the American Clinical and Climatological Association*, **2004**, 115, 233-47; discussion 247-8	0.9	26
172	Heterogeneity of antigen expression in advanced epithelial ovarian cancer. *American Journal of Obstetrics and Gynecology*, **1990**, 162, 883-8	6.4	25
171	Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. *International Journal of Gynecological Cancer*, **2016**, 26, 1070-7	3.5	25
170	Clinical application of oxaliplatin in epithelial ovarian cancer. *International Journal of Gynecological Cancer*, **2006**, 16, 1717-32	3.5	24
169	Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. *International Journal of Cancer*, **1989**, 43, 55-60	7.5	24
168	Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. *Journal of Cellular Physiology*, **1987**, 131, 36-42	7	24
167	In vitro assay of endotoxin by the inhibition of macrophage migration. *Journal of Bacteriology*, **1967** , 93, 15-20	3.5	24
166	Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. *Cell Cycle*, **2006**, 5, 1654-61	4.7	23

165	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer*, **2019**, 125, 1963-1972	6.4	22
164	The biology of ovarian cancer. *Current Opinion in Oncology*, **1993**, 5, 900-7	4.2	22
163	Ploidy analysis of epithelial ovarian cancers using image cytometry. *Gynecologic Oncology*, **1992**, 44, 61-5	4.9	22
162	The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. *Biochemical and Biophysical Research Communications*, **1987**, 149, 969-74	3.4	22
161	Biomarkers and Strategies for Early Detection of Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2504-2512	4	22
160	DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. *Cell Reports*, **2019**, 29, 3448-3459.e6	10.6	22
159	ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. *Bioscience Reports*, **2009**, 30, 159-68	4.1	21
158	Is OVX1 a suitable marker for endometrial cancer?. *Gynecologic Oncology*, **1997**, 65, 291-6	4.9	21
157	Specific keynote: molecular therapeutics in ovarian cancer. *Gynecologic Oncology*, **2003**, 88, S88-92; discussion S93-6	4.9	21
156	Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. *Journal of Biomedical Optics*, **2002**, 7, 20-6	3.5	21
155	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. *International Journal of Cancer*, **2000**, 89, 519-523	7.5	21
154	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. *International Journal of Cancer*, **1999**, 82, 525-31	7.5	21
153	A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. *Stem Cells and Development*, **1996**, 5, 57-62		21
152	High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. *Cancer Chemotherapy and Pharmacology*, **1989**, 23, 377-83	3.5	21
151	The role of tumor markers in gynecologic oncology. *Obstetrical and Gynecological Survey*, **1990**, 45, 570-7	2.4	21
150	SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. *International Journal of Cancer*, **2020**, 146, 1553-1567	7.5	21
149	The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. *Cell Adhesion and Migration*, **2013**, 7, 232-6	3.2	20
148	Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. *Journal of Hematology and Oncology*, **2010**, 3, 9	22.4	20

147	Long-term follow-up of the Stockholm screening study on ovarian cancer. *Gynecologic Oncology*, **2000**, 79, 466-70	4.9	20
146	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. *Cancer*, **1999**, 86, 1251-7	6.4	20
145	Expression of cell regulatory proteins in ovarian borderline tumors. *Cancer*, **1996**, 77, 2092-8	6.4	20
144	Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. *International Journal of Cancer*, **1991**, 49, 704-10	7.5	20
143	Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. *Oncotarget*, **2017**, 8, 17960-17980	5.3	20
142	Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. *Clinical Cancer Research*, **2018**, 24, 5072-5084	12.9	19
141	Novel Approaches to Ovarian Cancer Screening. *Current Oncology Reports*, **2019**, 21, 75	6.3	19
140	Conquering cancer in our lifetime: new diagnostic and therapeutic trends. *Clinical Chemistry*, **2013**, 59, 1-3	5.5	19
139	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. *Gynecologic Oncology*, **2008**, 108, 652-7	4.9	19
138	Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. *Bone Marrow Transplantation*, **2004**, 33, 1219-24	4.4	19
137	Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. *Cancer*, **1991**, 68, 1272-8	6.4	19
136	Targeting Aurora kinases in ovarian cancer. *Expert Opinion on Therapeutic Targets*, **2006**, 10, 77-85	6.4	18
135	Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. *American Journal of Obstetrics and Gynecology*, **1983**, 146, 607-12	6.4	18
134	A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. *American Journal of Obstetrics and Gynecology*, **1985**, 152, 911-3	6.4	18
133	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. *PLoS ONE*, **2015**, 10, e0131833	3.7	18
132	Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. *BMC Cancer*, **2016**, 16, 824	4.8	17
131	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. *Frontiers in Oncology*, **2013**, 3, 58	5.3	17
130	Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. *Gynecologic Oncology*, **1996**, 61, 233-40	4.9	17

129	Molecular approaches to prevention and detection of epithelial ovarian cancer. *Journal of Cellular Biochemistry*, **1995**, 23, 219-22	4.7	17
128	A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. *International Journal of Cancer*, **1992**, 51, 772-9	7.5	17
127	Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. *Journal of the National Cancer Institute*, **1975**, 55, 1345-52	9.7	17
126	Induction of tumor immunity by intratumoral chemotherapy. *Annals of the New York Academy of Sciences*, **1976**, 276, 565-72	6.5	17
125	Heregulin-induced apoptosis. *Apoptosis: an International Journal on Programmed Cell Death*, **2002**, 7, 483-91	5.4	16
124	In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. *Gynecologic Oncology*, **2005**, 98, 182-92	4.9	16
123	High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. *Gynecologic Oncology*, **2001**, 82, 420-6	4.9	16
122	Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. *Acta Oncologica*, **1998**, 37, 629-40	3.2	16
121	Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. *American Journal of Clinical Pathology*, **1993**, 99, 736-40	1.9	16
120	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. *Cancer*, **1995**, 76, 1615-20	6.4	16
119	Oncogenes in Ovarian Cancer. *Hematology/Oncology Clinics of North America*, **1992**, 6, 813-827	3.1	16
118	Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. *Annals of Surgery*, **1985**, 202, 440-5	7.8	16
117	The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. *Cancer*, **2019**, 125, 1267-1280	6.4	16
116	In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. *PLoS Genetics*, **2020**, 16, e1008808	6	15
115	Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. *Medical Oncology*, **2016**, 33, 73	3.7	15
114	In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. *ACS Applied Materials & Interfaces*, **2017**, 9, 41680-41690	9.5	15
113	A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies. *Biometrics*, **2010**, 66, 1275-83	1.8	15
112	Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. *Methods in Enzymology*, **2006**, 407, 660-76	1.7	15

111	Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. *Bioconjugate Chemistry*, **2018**, 29, 3180-3195	6.3	15
110	The origin of ovarian cancer. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2012**, 119, 134-6	3.7	14
109	Project Zero Delay: a process for accelerating the activation of cancer clinical trials. *Journal of Clinical Oncology*, **2009**, 27, 4433-40	2.2	14
108	Reproducibility of SELDI Spectra Across Time and Laboratories. *Cancer Informatics*, **2011**, 10, 45-64	2.4	14
107	OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. *Clinical Chemistry*, **1999**, 45, 692-694	5.5	14
106	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. *International Journal of Cancer*, **1994**, 59, 242-7	7.5	14
105	Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. *American Journal of Obstetrics and Gynecology*, **1989**, 161, 1258-63	6.4	14
104	Gynecologic tumor markers. *Journal of Surgical Oncology*, **1990**, 6, 305-13		14
103	Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. *Cancer*, **2020**, 126, 725-736	6.4	14
102	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. *Clinical Cancer Research*, **2019**, 25, 5702-5716	12.9	14
101	Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. *Cancers*, **2019**, 11,	6.6	13
100	A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 1033-44	3.5	13
99	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. *Cell Cycle*, **2010**, 9, 140-6	4.7	13
98	Ovarian cancer identified through screening with serum markers but not by pelvic imaging. *International Journal of Gynecological Cancer*, **1999**, 9, 497-501	3.5	13
97	Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. *Gynecologic Oncology*, **1994**, 53, 59-63	4.9	13
96	Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. *Journal of Clinical Oncology*, **1992**, 10, 1057-65	2.2	13
95	Antigenic heterogeneity in human ovarian cancer. *Gynecologic Oncology*, **1990**, 38, 12-6	4.9	13
94	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. *Cancer Prevention Research*, **2019**, 12, 391-400	3.2	12

93	Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. *Cancer Biology and Therapy*, **2012**, 13, 1034-41	4.6	12
92	Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. *Biochemical Journal*, **2000**, 352, 475	3.8	12
91	Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. *International Journal of Immunopharmacology*, **1983**, 5, 307-14		12
90	Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. *Cancers*, **2019**, 11,	6.6	11
89	Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. *International Journal of Cancer*, **1987**, 40, 592-7	7.5	11
88	Nature of the immunogen in crystalline serum albumins. *Immunochemistry*, **1970**, 7, 118-24		11
87	DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. *Cancers*, **2019**, 11,	6.6	10
86	Molecular approaches to management of epithelial ovarian cancer. *International Journal of Gynecological Cancer*, **2000**, 10, 2-7	3.5	10
85	Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. *Journal of the National Cancer Institute*, **1974**, 53, 591-3	9.7	10
84	Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. *Journal of Clinical Investigation*, **1993**, 92, 2440-7	15.9	10
83	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. *Cancer*, **2015**, 121, 806-16	6.4	9
82	Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. *Molecular Medicine Reports*, **2010**, 3, 581-7	2.9	9
81	Specific keynote: chemoprevention of ovarian cancer: the journey begins. *Gynecologic Oncology*, **2003**, 88, S59-66; discussion S67-70	4.9	9
80	Translational research--traffic on the bridge. *Biomedicine and Pharmacotherapy*, **2001**, 55, 565-71	7.5	9
79	Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. *American Journal of Obstetrics and Gynecology*, **1996**, 174, 1316-9	6.4	9
78	OVX1 as a marker for early stage endometrial carcinoma. *Cancer*, **1994**, 73, 1855-8	6.4	9
77	Antigenic heterogeneity among Burkitt© lymphoma cells surviving treatment with monoclonal antibody and complement. *Leukemia Research*, **1986**, 10, 35-42	2.7	9
76	NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. *Oncotarget*, **2016**, 7, 3018-32	3.3	9

75	Targeting progesterone signaling prevents metastatic ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 31993-32004	11.5	9
74	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-□*Investigational New Drugs*, **2018**, 36, 1103-1109	4.3	9
73	Communication skills training in oncology **1999**, 86, 887		9
72	Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. *Journal of Geriatric Oncology*, **2019**, 10, 705-708	3.6	8
71	Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12121-12130	11.5	8
70	Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. *Oncogene*, **2000**, 19, 6277-85	9.2	8
69	The use of tumor markers in the management of patients with gynecologic carcinomas. *Clinical Obstetrics and Gynecology*, **1992**, 35, 45-54	1.7	8
68	Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. *Journal of the National Cancer Institute*, **1980**, 64, 365-72	9.7	8
67	Directed evolution of cyclic peptides for inhibition of autophagy. *Chemical Science*, **2021**, 12, 3526-3543	9.4	8
66	Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. *Cancer*, **2020**, 126, 3579-3592	6.4	7
65	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. *Cancers*, **2020**, 12,	6.6	7
64	Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. *American Journal of Obstetrics and Gynecology*, **2014**, 210, 257.e1-6	6.4	7
63	Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. *Cancer Investigation*, **2001**, 19, 459-66	2.1	7
62	High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. *Bone Marrow Transplantation*, **2000**, 25, 1137-40	4.4	7
61	Progress in radioimmunotherapy. *New England Journal of Medicine*, **1993**, 329, 1266-8	59.2	7
60	Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. *Cancer*, **1992**, 70, 2137-42	6.4	7
59	Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma. *Journal of the National Cancer Institute*, **1975**, 55, 989-94	9.7	7
58	Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. *Frontiers in Bioscience - Landmark*, **2007**, 12, 2260-8	2.8	7

57	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. *Cancers*, **2020**, 12,	6.6	7
56	4-HPR modulates gene expression in ovarian cells. *International Journal of Cancer*, **2006**, 119, 1005-13	7.5	6
55	The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. *American Journal of Obstetrics and Gynecology*, **1992**, 167, 1877-82	6.4	6
54	Destruction of syngeneic tumors by tuberculin-stimulated peritoneal exudate cells from guinea pigs immunized to Mycobacterium bovis (strain BCG). *Journal of the National Cancer Institute*, **1974**, 53, 541-6	9.7	6
53	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. *Cancer*, **1995**, 76, 2092-2096	6.4	6
52	Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. *Cancer Prevention Research*, **2019**, 12, 171-184	3.2	5
51	Clinical applications of monoclonal antibodies in acute leukemia. *Annals of the New York Academy of Sciences*, **1984**, 428, 308-17	6.5	5
50	Radioiodinated antibody targeting of the HER-2/neu oncoprotein. *Nuclear Medicine and Biology*, **1997**, 24, 451-9	2.1	5
49	A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. *Cancers*, **2021**, 13,	6.6	5
48	Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. *Gynecologic Oncology*, **1998**, 70, 49-55	4.9	4
47	Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. *Cancer*, **1992**, 69, 2894-904	6.4	4
46	Monitoring Epithelial Ovarian Cancer. *Laboratory Medicine*, **1985**, 16, 315-318	1.6	4
45	Intracolonic injection of BCG in the rhesus monkey. *Journal of the National Cancer Institute*, **1974**, 53, 1423-6	9.7	4
44	Monoclonal Serotherapy **2017**, 1-23		3
43	Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. *Clinical Ovarian Cancer & Other Gynecologic Malignancies*, **2010**, 3, 81-97		3
42	Biomarkers and clinical trial design. *Gynecologic Oncology*, **2006**, 103, S3-5	4.9	3
41	Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. *Methods in Molecular Medicine*, **2001**, 39, 37-48		3
40	Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. *BMJ: British Medical Journal*, **1993**, 306, 1684-5		3

39	Biology and therapy with biologic agents in gynecologic cancer. *Current Opinion in Oncology*, **1992**, 4, 946-54	4.2	3
38	The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. *Chemico-Biological Interactions*, **1976**, 14, 379-82	5	3
37	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. *Oncogenesis*, **2021**, 10, 65	6.6	3
36	Molecular Diagnostics in Cancer **2017**, 1-14		2
35	Molecular Pathogenesis of Ovarian Cancer **2015**, 531-548.e2		2
34	Conclusions and recommendations from the Helene Harris Memorial Trust SixthBiennial International Forum on Ovarian Cancer, May 10-14, 1997, LosAngeles, California, USA. *International Journal of Gynecological Cancer*, **1997**, 7, 416-424	3.5	2
33	General keynote: molecular therapeutics and pharmocogenomics. *Gynecologic Oncology*, **2003**, 88, S84-7; discussion S93-6	4.9	2
32	Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. *International Journal of Gynecological Cancer*, **1996**, 6, 156-158	3.5	2
31	Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. *Cancer*, **1992**, 70, 1115-23	6.4	2
30	CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. *American Journal of Obstetrics and Gynecology*, **1989**, 160, 354-5	6.4	2
29	Reactivity of Polyclonal and Two Monoclonal Antibodies with Cell Subsets Isolated from Cystic Fluids of Ovarian Serous Neoplasms. *Tumori*, **1990**, 76, 505-510	1.7	2
28	Reply to Davies et al. *American Journal of Obstetrics and Gynecology*, **1985**, 151, 420	6.4	2
27	New approach to serotherapy of human ovarian carcinoma. *Gynecologic Oncology*, **1980**, 10, 370	4.9	2
26	Abstract 2838: TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer **2015**,		2
25	Abstract 1864: Feasibility of magnetic relaxometry for early ovarian cancer detection: preliminary evaluation of sensitivity and specificity in cell culture and in mice **2017**,		2
24	The National Cancer Institute Early Detection Research Network: Two Decades of Progress. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2396-2400	4	2
23	A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. *Cancers*, **2021**, 13,	6.6	2
22	Tumor suppressor genes. *Cancer Treatment and Research*, **2009**, 149, 109-29	3.5	2

21	Recent advances in the immunodiagnosis of epithelial ovarian carcinoma. *Cancer Treatment and Research*, **1985**, 23-35	3.5	2
20	The Immunobiology of Ovarian Carcinoma. *Cancer Treatment and Research*, **1983**, 187-226	3.5	2
19	Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" 2019, , 596: Markers for Early Detection of Ovarian Cancer. *Cancers*, **2019**, 11,	6.6	1
18	Cancer Stem Cell Principles **2015**, 39-46		1
17	Molecular Pathogenesis of Epithelial Ovarian Cancer **2008**, 441-454		1
16	Ha-ras polymorphisms in epithelial ovarian cancer. *Gynecologic Oncology*, **1992**, 45, 299-302	4.9	1
15	Validation of a multi-marker panel for early detection of ovarian cancer.. *Journal of Clinical Oncology*, **2016**, 34, 5570-5570	2.2	1
14	Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry.. *Journal of Clinical Oncology*, **2018**, 36, e13019-e13019	2.2	1
13	DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. *Molecular Cancer Therapeutics*, **2021**,	6.1	1
12	Next steps in the early detection of ovarian cancer. *Communications Medicine*, **2021**, 1,		1
11	Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.. *Tumor Biology*, **2021**, 43, 355-365	2.9	1
10	Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer **2017**, 1-27		0
9	Recurrent Ovarian Cancer: When to Treat and How to Assess **2014**, 17-27		
8	Targeting therapies in cancer: opportunities in ovarian cancer167-182		
7	p27Kip1 as a Biomarker and Target for Treatment of Cancer **2010**, 215-233		
6	Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer **2004**, 625-645		
5	Characterization of the ARHI Tumor-Suppressor as a Target for Gene Therapy in Ovarian Cancer*. *Geburtshilfe Und Frauenheilkunde*, **2002**, 62, 870-876	2	
4	Clinical and laboratory directions for ovarian cancer research. *Gynecologic Oncology*, **1994**, 55, S164-7	4.9	

3 Molecular targets for epithelial ovarian cancer606-618

2 Ovarian Cancer Screening **2010**, 87-107

1 The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy **2014**, 99-109